| Change in the spectrum of RET mutations diagnosed between 1994 and 2006. | None |
| a change in the spectrum of mutations detected in the RET proto-oncogene in patients with hereditary MTC from the _classical_ mutation at codon 634 in exon 11 (level 2) to more cases with mutations in the exons 13-15 (level 1) and less aggressive disease | None |
| [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees]. | None |
| Formation of pseudosymmetrical G-quadruplex and i-motif structures in the proximal promoter region of the RET oncogene. | None |
| [DelD631: a novel mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN2A)]. | None |
| RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. | None |
| [Mutation of the RET proto-oncogene in type 2A multiple endocrine neoplasia Chinese families and the application of pentagastrin stimulation test in diagnosis and follow-up]. | None |
| Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene. | None |
| Oncogenic RET mutations may, however, vary between specific population groups. RET analysis in MEN has revolutionized the management of children of MEN2 and allowed surgical prediction and prophylaxis to take place. | None |
| The RET proto-oncogene has become the target for molecularly designed drug therapy. Tyrosine kinase inhibitors targeting activated RET are currently in clinical trials for the treatment of patients with MTC. | None |
| Enhanced sensitivity of the RET proto-oncogene to ionizing radiation in vitro. | None |
| XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. | None |
| Analysis of RET, ZEB2, EDN3 and GDNF genomic rearrangements in 80 patients with Hirschsprung disease (using multiplex ligation-dependent probe amplification). | None |
| Genetic testing for multiple endocrine neoplasia type 2. | None |
| Missense mutations in RET proto-oncogene correlated with pathology and diagnosis of Multiple endocrine neoplasia type 2 carriers | None |
| Genetic testing is essential in patients with confirmed MTC, and should be extended to all first degree relatives when a RET proto-oncogene mutation is discovered. Early prophylactic surgery is the definitive treatment for carriers of RET mutations. | None |
| Mutations in the RET proto-oncogene is associated with multiple endocrine neoplasia type 2A. | None |
| The ret oncogene products are membrane-bound glycoproteins phosphorylated on tyrosine residues in vivo. | None |
| A TaqI RFLP in the human ret proto-oncogene. | None |
| Molecular analyses revealed an oncogenic potential for all the novel germline RET variants. The prevalence of exon 8 genomic variations with an oncogenic potential may be higher than previously thought. | None |